Participants Sought for Clinical Trial of SMA Muscle Therapy Apitegromab | mySMAteam

Connect with others who understand.

sign up Log in
Resources
About mySMAteam
Powered By
SMA
NEWS

Participants Sought for Clinical Trial of SMA Muscle Therapy Apitegromab

Medically reviewed by Amit M. Shelat, D.O.
Written by Maureen McNulty
Posted on December 22, 2021

  • Pharmaceutical company Scholar Rock is seeking participants for a clinical trial of apitegromab, a new treatment for spinal muscular atrophy (SMA).
  • Previous studies show that apitegromab can lead to motor-function improvements when used along with existing SMA drugs.
  • People living with SMA who are interested in participating in the study and meet the criteria should speak with their health care provider.

Scholar Rock will soon start enrolling participants for a phase 3 clinical trial of apitegromab, a new muscle therapy. For the trial — dubbed SAPPHIRE — apitegromab will be tested alongside other medications for people with type 2 and type 3 SMA who are nonambulatory (unable to walk).

During the study, apitegromab will be tested in tandem with two existing SMA treatments: Spinraza (nusinersen) and Evrysdi (risdiplam). This usage of an additional treatment may be referred to as add-on, adjuvant, or augmentation therapy. The trial will test whether apitegromab is safe for people with SMA to take and whether the drug is effective at improving motor skills.

Currently, the trial is estimated to begin in February 2022 and last for 12 months. Participants will then have a 20-week follow-up period or have the option to enroll into an extension study.

A New Approach To Treating SMA

Apitegromab works differently than other SMA drugs. Current treatment options like nusinersen and risdiplam work by helping nerve cells make more survival motor neuron (SMN) protein, which helps protect the nerves from dying. Apitegromab, on the other hand, targets muscle cells. It blocks a protein called myostatin that prevents muscles from growing.

In theory, a treatment plan that includes both apitegromab and other SMA treatments may help protect both nerve cells and muscle cells, leading to better motor function in people with SMA. However, additional clinical trials are needed to test the safety and effectiveness of this treatment plan.

In an initial study, researchers gave apitegromab to 58 people with type 2 or type 3 SMA. The study participants received apitegromab intravenously (through an IV) once every four weeks.

The researchers found that apitegromab was safe and effective. More than half of the study participants had improvements in physical function, and the researchers didn’t find any major side effects that seemed to be associated with the drug.

Share your thoughts with others. Click here to add a comment.

Study Details and Eligibility Criteria

Scholar Rock has laid out details about the new apitegromab clinical trial. The company expects to enroll about 156 people between the ages of 2 and 12 with type 2 or 3 SMA.

During the 12-month trial, each participant will receive standard SMA treatments in addition to one of the following options:

  • A lower dose of apitegromab
  • A higher dose of apitegromab
  • A placebo (a compound that doesn’t have any medical effect)

As participants receive treatment, researchers will collect information about motor function, developmental milestones, and side effects.

Scholar Rock will also conduct a smaller study with 48 people with type 2 or 3 SMA who are between the ages of 13 and 21. These participants will either receive a high dose of apitegromab or placebo.

According to Scholar Rock, people interested in participating in the trial should speak with their health care provider. More information will be posted on the study’s ClinicalTrials.gov page.

Posted on December 22, 2021
All updates must be accompanied by text or a picture.

Become a Subscriber

Get the latest news about spinal muscular atrophy sent to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Amit M. Shelat, D.O. is a fellow of the American Academy of Neurology and the American College of Physicians. Review provided by VeriMed Healthcare Network. Learn more about him here
Maureen McNulty studied molecular genetics and English at Ohio State University. Learn more about her here

Recent Articles

Welcome to mySMAteam — the place to connect with others living with spinal muscular atrophy. Thi...

Getting Started on mySMAteam (VIDEO)

Welcome to mySMAteam — the place to connect with others living with spinal muscular atrophy. Thi...
If you’re living with spinal muscular atrophy (SMA), you can have a happy and healthy pregnancy, ...

6 Facts About Pregnancy With SMA

If you’re living with spinal muscular atrophy (SMA), you can have a happy and healthy pregnancy, ...
Magnetic resonance imaging (MRI) is a powerful imaging technique for visualizing the muscles, org...

Can MRI Detect Spinal Muscular Atrophy?

Magnetic resonance imaging (MRI) is a powerful imaging technique for visualizing the muscles, org...
If you or a loved one is living with spinal muscular atrophy (SMA), you may be researching to lea...

SMA and ALS: 5 Differences and 3 Similarities

If you or a loved one is living with spinal muscular atrophy (SMA), you may be researching to lea...
If your child was recently diagnosed with spinal muscular atrophy (SMA) — or if you were recently...

Can You Walk With Spinal Muscular Atrophy? 4 Things To Know

If your child was recently diagnosed with spinal muscular atrophy (SMA) — or if you were recently...
This is a short guided meditation by Dr. Christiane Wolf on self-kindness, which gives you more s...

Self-Kindness When Struggling: 6-Minute Guided Meditation

This is a short guided meditation by Dr. Christiane Wolf on self-kindness, which gives you more s...
SMA News
SMA News

Thank you for subscribing!

Become a member to get even more:

sign up for free

close